entertainment -WSS

entertainment

author：leisure time 2025-10-01 21:09:14 - browse：259

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： ALS patient reclaims some autonomy thanks to wearable 'robot'

hotspot

WSS

Getting Alzheimer's drug Leqembi to patients can be a challenge

Why does health care cost so much? A reading guide

5 takeaways from STAT's examination of Zynex Medical

Medical bills so high, Medicare adding extra digits to claim forms

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

focus

entertainment

explore

Walensky prepares to leave CDC — and Congress — behind

Bird flu in milk supply is likely coming from asymptomatic cows

Novavax promises a turnaround & Lilly roils the obesity market

Why rehabilitation engineers need to center patients in their research

Activists slam private health insurers over coverage restrictions

ALS patient reclaims some autonomy thanks to wearable 'robot'

Wildfire smoke exposes gaps in outdoor worker protections

Cell therapy fails to slow type 1 diabetes, but safety is established

Dobbs anniversary: the lost opportunity of abortion as health care

Study: Why relieving medical debt did not improve financial outcomes

focus

Diversity in clinical trials starts with building trust, experts say

Teladoc has a new CEO, but challenges remain the same

Readers discuss the intersection of pregnancy and addiction

Cheap, fast test for Zika and dengue could cost just $1

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Curing rare childhood diseases will falter unless Congress steps up

hotspot

knowledge

hotspot

hotspot